Simfibrate
Chemical compound
- C10AB06 (WHO)
- Propane-1,3-diyl bis[2-(4-chlorophenoxy)-2-methylpropanoate]
- 14929-11-4
- 5217
- 5028
Y
- L2R75RQX26
- D01212 Y
- DTXSID8057647
- Interactive image
- Clc2ccc(OC(C(=O)OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)(C)C)cc2
InChI
- InChI=1S/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3Y
- Key:JLRNKCZRCMIVKA-UHFFFAOYSA-NY
Simfibrate (JAN/INN; trade name Cholesolvin) is a fibrate that has been used for the treatment of hyperlipidemia.[1][2] The substance is a double ester of clofibric acid with 1,3-propanediol which is cleaved in the body to one molecule of 1,3-propanediol and two molecules of clofibric acid which is the true lipid-lowering agent.
References
- ^ Verma N (2016). "Introduction to Hyperlipidemia and its Treatment: A Review". International Journal of Current Pharmaceutical Research. 9: 6. doi:10.22159/ijcpr.2017v9i1.16616.
- ^ Olsson AG, Orö L, Rössner S (1974). "Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate". Atherosclerosis. 19 (3): 407–15. doi:10.1016/S0021-9150(74)80005-5. PMID 4364073.
- v
- t
- e
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
